Global Finance News
07 Oct 2026, 16:57
Danaher Launches AI-Powered Autonomous Lab to Accelerate Life Sciences Research
Danaher (NYSE: DHR) announced plans to launch its first AI-powered autonomous laboratory, combining artificial intelligence, robotics and technologies from across its life sciences portfolio to accelerate the development of antibodies and other molecular research tools.
The lab is expected to operate at scale in early 2027 and is designed to make affinity reagent discovery up to eight times faster. Danaher also expects the platform to increase annual reagent generation by as much as tenfold, moving from tens to potentially hundreds of reagents per year.
Based at Danaher-owned Abcam, the system will use AI to design new affinity reagents, manufacture and test them, and then feed experimental results back into the model to improve subsequent designs. The workflow combines technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices, with robotic automation developed in collaboration with Automata.
The continuous “design-make-test-learn” process is intended to reduce development cycles while preserving scientific validation. Danaher said scientists will continue to make key decisions, while automation handles more repetitive experimentation and data generation.
The project is also part of a broader strategy to develop smart laboratory instruments capable of producing AI-ready data, operating through agentic systems and connecting into integrated autonomous workflows. Danaher said these systems could make research more predictive, standardized and efficient by helping prioritize promising experimental designs before physical testing.
The initiative strengthens Danaher’s positioning at the intersection of life sciences, laboratory automation and AI, with the company aiming to shorten the path from scientific idea to validated research result.
Danaher (NYSE: DHR) announced plans to launch its first AI-powered autonomous laboratory, combining artificial intelligence, robotics and technologies from across its life sciences portfolio to accelerate the development of antibodies and other molecular research tools.
The lab is expected to operate at scale in early 2027 and is designed to make affinity reagent discovery up to eight times faster. Danaher also expects the platform to increase annual reagent generation by as much as tenfold, moving from tens to potentially hundreds of reagents per year.
Based at Danaher-owned Abcam, the system will use AI to design new affinity reagents, manufacture and test them, and then feed experimental results back into the model to improve subsequent designs. The workflow combines technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices, with robotic automation developed in collaboration with Automata.
The continuous “design-make-test-learn” process is intended to reduce development cycles while preserving scientific validation. Danaher said scientists will continue to make key decisions, while automation handles more repetitive experimentation and data generation.
The project is also part of a broader strategy to develop smart laboratory instruments capable of producing AI-ready data, operating through agentic systems and connecting into integrated autonomous workflows. Danaher said these systems could make research more predictive, standardized and efficient by helping prioritize promising experimental designs before physical testing.
The initiative strengthens Danaher’s positioning at the intersection of life sciences, laboratory automation and AI, with the company aiming to shorten the path from scientific idea to validated research result.
